United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biopharmaceutical Company Ajax Therapeutics for $2.3 Billion in All-Cash Deal (Include Contingents), Ajax Therapeutics Founded in 2019 by Martin Vogelbaum
2nd May 2026 | Hong Kong
United States biopharmaceutical giant Eli Lilly ($808 billion market value) has announced to buy United States clinical-stage biopharmaceutical company Ajax Therapeutics for $2.3 billion in all-cash deal cash (Include contingent). Ajax Therapeutics was founded in 2019 by Martin Vogelbaum and 5 scientific founders including Ross Levine (MD, Chief Scientific Officer at Memorial Sloan Kettering Cancer Center). Ajax Therapeutics – Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel next generation therapies for myeloproliferative neoplasms (MPNs), including myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational structure-based drug discovery platforms from our founding collaboration partner, Schrödinger, Inc, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs. Eli Lilly – Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
“ United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biopharmaceutical Company Ajax Therapeutics for $2.3 Billion in All-Cash Deal (Include Contingents), Ajax Therapeutics Founded in 2019 by Martin Vogelbaum “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
United States $808 Billion Biopharmaceutical Giant Eli Lilly Buys United States Clinical-Stage Biopharmaceutical Company Ajax Therapeutics for $2.3 Billion in All-Cash Deal (Include Contingents), Ajax Therapeutics Founded in 2019 by Martin Vogelbaum
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
